Physician profile
Robert A Silverman
NPI 1841394491
$3,721.00
in general payments reported to CMS, 2019-2025
41 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $586 · 2021: $893 · 2022: $461 · 2023: $642 · 2024: $248 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,070 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,069.54 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $547.92 | 2019-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $438.83 | 2019-2023 | Breztri |
| Novo Nordisk INC | $396.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $354.48 | 2019-2022 | |
| Lilly USA, LLC | $271.69 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $256.28 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $166.69 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $127.31 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $120.46 | 2022 | |
| Mannkind Corporation | $105.78 | 2023 | Afrezza |
| Astellas Pharma US INC | $84.37 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $82.34 | 2019-2025 | Gardasil 9, Capvaxive |
| Abbvie INC. | $62.40 | 2021 | |
| Boston Scientific Corporation | $61.96 | 2020-2024 | Watchman Access System, Vigilant X4 Crt-D |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.00 | 2019-2023 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.